Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-09-19
2000-08-01
Cook, Rebecca
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31445
Patent
active
060967595
ABSTRACT:
This invention relates to the treatment of essential hypertension by administration of anti-hypertensive effective amounts of 4-hydroxy-2,2,6,6-tetramethyl-1-piperidine-1-oxyl (tempol).
REFERENCES:
patent: 4046901 (1977-09-01), Nedelec et al.
patent: 5034395 (1991-07-01), Tamada et al.
patent: 5332577 (1994-07-01), Gertner
patent: 5462946 (1995-10-01), Mitchell et al.
patent: 5516881 (1996-05-01), Lee et al.
patent: 5541163 (1996-07-01), Lavalle e et al.
patent: 5543422 (1996-08-01), Coutts et al.
patent: 5591710 (1997-01-01), Hsia
patent: 5622994 (1997-04-01), Carney et al.
patent: 5725839 (1998-03-01), Hsia
patent: 5741893 (1998-04-01), Hsia
patent: 5767089 (1998-06-01), Hsia
patent: 5804561 (1998-09-01), Hsia
patent: 5807831 (1998-09-01), Hsia
Tab, Neuroreport 7 (8) 1382-4 May 31, 1996.
Karmeli et al, GUT, 38(6) 826-31 Jun. 1996.
Monte et al, Free Radical Biol. Med., 21(4) 463-470 1996.
C.J. Bulpitt et al., "Vitamin C and blood pressure," J. Hypertens, 8(12):1071-5 (1990).
D. Giugliano et al., "Diabetes Mellitus, hypertension, and cardiovascular disease: which role for oxidative stress?." Metabolism 44(3):363-8 (1995).
S. Grunfeld et al., "Role of Superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats," Hypertension 26(6 Pt 1):854-7 (1995).
R.J. Gryglewski et al., "Superoxide anion is involved in the breakdown of endothelium--derived vascular relaxing factor," Nature 320(6061): 454-6 (1986).
D.G. Harrison et al., "Physiologic consequences of increased vascular oxidant stresses in hypercholesterolemia and atherosclerosis: implications for impaired vasomotion," Am. J. Cardiol 75(6): 75B-81B (1995).
V.V. Khramtsov et al., "In vitro and in vivo studies of the derivatives of 1,2-diazetine and nitronylnitroxide as donors and acceptors of nitric oxide," Biokhimiya, 61(10): 1731-1742 (1996).
K.V. Kumar et al., "Are free radicals involved in the pathobiology of human essential hypertension?," Ree Radic Res Commun. 19(1): 59-66 (1993).
J. M. McCord, "Oxygen-derived free radicals in postischermic tissue injury," N. Engl. J. Med. 312(3): 159-63 (1985).
Y. Miyamoto et al., "Potentiation of nitric oxide-mediated vasorelaxation by xanthine oxidase inhibitors," Proc. Soc. Exp. Biol. Med. 312(4): 366-373 (1996).
K. Nakazono et al., "Does superoxide underlie the pathogenesis of hypertension?" Proc. Natl. Acad. Sci. USA 88: 10045-10048 (1991).
G.M. Rubanyi et al., "Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor," Am. J. Physiol. 250: H822-H827 (1986).
C.G. Schnackenberg et al., "Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic," Hypertension, 32(1): 59-64 (1998).
C.G. Schnackenberg et al., "Long-term tempol administration attenuates the hypertension and production of 8-iso prostaglandin F2a in SHR." Hypertension 32(3): 622 (1998).
H. Suzuki et al., "In vivo evidence for microvascular oxidative stress in spontaneously hypertensive rats, Hydroethidine microfluorography," Hypertension 25(5): 1083-1089 (1995).
M.R. Tschudi et al., "Direct in situ measurement of nitric oxide in mesenteric arteries. Increased decomposition by superoxide in hypertension." Hypertension 27(1): 32-35 (1996).
W.Y Tse et al., "Antioxidant status in controlled and uncontrolled hypertension and its relationship to endothelial damage." J. Hum. Hypertens. 89:843-849 (1994).
M. Yoshioka et al., "Effects of ascorbic acid on blood pressure and ascorbic acid metabolism in spontaneously hypertensive rates (SH Rats)." Internat. J. Vit. Nutr. Res. 55:301-307 (1985).
Cook Rebecca
Georgetown University
LandOfFree
Method for treating essential hypertension does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating essential hypertension, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating essential hypertension will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-664342